SGAM
FPRX

Smith Group Asset Management’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Smith Group Asset Management’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-39,850
Closed -$990K – 440
2015
Q2 		$990K Buy
39,850
+600
+2% +$13.4K 0.03% 169
2015
Q1 		$897K Buy
+39,250
New +$991K 0.03% 178

Other funds holding FPRX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Smith Group Asset Management's FPRX Position: Q3 2015 in Review

Smith Group Asset Management sold out of Five Prime Therapeutics, Inc. (FPRX) in Q3 2015, closing a stake of 39,850 shares — an estimated $990K sold.

Smith Group Asset Management first reported a position in FPRX in Q1 2015 and held it in 2 quarters. The position peaked at $990K in Q2 2015. 111 funds tracked by Wall St. Rank hold FPRX as of Q3 2015.

  • Smith Group Asset Management reported no remaining Five Prime Therapeutics, Inc. position as of Q3 2015 after selling out during the quarter.
  • Smith Group Asset Management sold 39,850 Five Prime Therapeutics, Inc. shares in Q3 2015, an estimated $990K.
  • Smith Group Asset Management first reported a position in Five Prime Therapeutics, Inc. in Q1 2015 and held it in 2 quarters.
  • Smith Group Asset Management's Five Prime Therapeutics, Inc. position peaked at $990K in Q2 2015.
  • 111 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q3 2015.

Based on Smith Group Asset Management's 13F filing for Q3 2015, filed 23 Oct 2015.